OSAKA, Japan & CAMBRIDGE, Massachusetts – (BUSINESS WIRE) – Takeda Pharmaceutical Company Limited (TSE: 4502 / NYSE: TAK) (“Takeda”) zal virtueel presenteren op de 39e jaarlijkse J.P. Morgan Healthcare Conference om 17:20 uur ET op maandag 11 januari 2021 / 7:20 uur JT op dinsdag 12 januari 2021. Investeerders en het grote publiek worden uitgenodigd om hier naar de live webcast te luisteren met Christophe Weber, president en chief executive officer. Een herhaling van de webcast wordt ook op dezelfde locatie gearchiveerd. Een link naar de webcast en slides om te downloaden zullen ook beschikbaar zijn op de website van Takeda op https://www.takeda.com/investors/ir-events/.

Takeda to Present at The 39th Annual J.P. Morgan Healthcare Conference

OSAKA, Japan & CAMBRIDGE, Mass.–(BUSINESS WIRE)– Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (“Takeda”) will present virtually at the 39th Annual J.P. Morgan Healthcare Conference at 5:20 p.m. ET on Monday, January 11, 2021 / 7:20 a.m. JT on Tuesday, January 12, 2021. Investors and the general public are invited to listen to the live webcast with Christophe Weber, president and chief executive officer, here. A replay of the webcast will also be archived at the same location. A link to the webcast and slides for download will also be available on Takeda’s website at https://www.takeda.com/investors/ir-events/.

ABOUT TAKEDA PHARMACEUTICAL COMPANY LIMITED

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit https://www.takeda.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005289/en/

Contacts

Media Contacts:
Japanese Media

Kazumi Kobayashi

kazumi.kobayashi@takeda.com
+81 (0) 3-3278-2095

Media Outside Japan

Holly Campbell

holly.campbell@takeda.com
+1 617-588-9013

Investor Relations:
Christopher O’Reilly

christopher.oreilly@takeda.com
+81 (0) 3-3278-2543